785 related articles for article (PubMed ID: 17275806)
1. Vasopressin promotes cardiomyocyte hypertrophy via the vasopressin V1A receptor in neonatal mice.
Hiroyama M; Wang S; Aoyagi T; Oikawa R; Sanbe A; Takeo S; Tanoue A
Eur J Pharmacol; 2007 Mar; 559(2-3):89-97. PubMed ID: 17275806
[TBL] [Abstract][Full Text] [Related]
2. Vasopressin stimulates insulin release from islet cells through V1b receptors: a combined pharmacological/knockout approach.
Oshikawa S; Tanoue A; Koshimizu TA; Kitagawa Y; Tsujimoto G
Mol Pharmacol; 2004 Mar; 65(3):623-9. PubMed ID: 14978240
[TBL] [Abstract][Full Text] [Related]
3. Impaired arginine-vasopressin-induced aldosterone release from adrenal gland cells in mice lacking the vasopressin V1A receptor.
Birumachi J; Hiroyama M; Fujiwara Y; Aoyagi T; Sanbe A; Tanoue A
Eur J Pharmacol; 2007 Jul; 566(1-3):226-30. PubMed ID: 17449028
[TBL] [Abstract][Full Text] [Related]
4. Leptin induces hypertrophy via endothelin-1-reactive oxygen species pathway in cultured neonatal rat cardiomyocytes.
Xu FP; Chen MS; Wang YZ; Yi Q; Lin SB; Chen AF; Luo JD
Circulation; 2004 Sep; 110(10):1269-75. PubMed ID: 15313952
[TBL] [Abstract][Full Text] [Related]
5. Atrial natriuretic peptide inhibits cardiomyocyte hypertrophy through mitogen-activated protein kinase phosphatase-1.
Hayashi D; Kudoh S; Shiojima I; Zou Y; Harada K; Shimoyama M; Imai Y; Monzen K; Yamazaki T; Yazaki Y; Nagai R; Komuro I
Biochem Biophys Res Commun; 2004 Sep; 322(1):310-9. PubMed ID: 15313208
[TBL] [Abstract][Full Text] [Related]
6. FAK-related nonkinase attenuates hypertrophy induced by angiotensin-II in cultured neonatal rat cardiac myocytes.
Qin J; Liu ZX
Acta Pharmacol Sin; 2006 Sep; 27(9):1159-64. PubMed ID: 16923336
[TBL] [Abstract][Full Text] [Related]
7. DY-9760e inhibits endothelin-1-induced cardiomyocyte hypertrophy through inhibition of CaMKII and ERK activities.
Lu YM; Shioda N; Han F; Kamata A; Shirasaki Y; Qin ZH; Fukunaga K
Cardiovasc Ther; 2009; 27(1):17-27. PubMed ID: 19207476
[TBL] [Abstract][Full Text] [Related]
8. JunD attenuates phenylephrine-mediated cardiomyocyte hypertrophy by negatively regulating AP-1 transcriptional activity.
Hilfiker-Kleiner D; Hilfiker A; Castellazzi M; Wollert KC; Trautwein C; Schunkert H; Drexler H
Cardiovasc Res; 2006 Jul; 71(1):108-17. PubMed ID: 16690042
[TBL] [Abstract][Full Text] [Related]
9. Effect of YM218, a nonpeptide vasopressin V(1A) receptor-selective antagonist, on rat mesangial cell hyperplasia and hypertrophy.
Tahara A; Tsukada J; Tomura Y; Suzuki T; Yatsu T; Shibasaki M
Vascul Pharmacol; 2007 Jun; 46(6):463-9. PubMed ID: 17395547
[TBL] [Abstract][Full Text] [Related]
10. Effect of YM087, a potent nonpeptide vasopressin antagonist, on vasopressin-induced protein synthesis in neonatal rat cardiomyocyte.
Tahara A; Tomura Y; Wada K; Kusayama T; Tsukada J; Ishii N; Yatsu T; Uchida W; Tanaka A
Cardiovasc Res; 1998 Apr; 38(1):198-205. PubMed ID: 9683922
[TBL] [Abstract][Full Text] [Related]
11. Dopamine D2 receptor stimulation inhibits angiotensin II-induced hypertrophy in cultured neonatal rat ventricular myocytes.
Li H; Shi S; Sun YH; Zhao YJ; Li QF; Li HZ; Wang R; Xu CQ
Clin Exp Pharmacol Physiol; 2009 Mar; 36(3):312-8. PubMed ID: 18986329
[TBL] [Abstract][Full Text] [Related]
12. Evidence for the existence of vasopressin V2 receptor mRNA in rat hippocampus.
Hirasawa A; Nakayama Y; Ishiharada N; Honda K; Saito R; Tsujimoto G; Takano Y; Kamiya H
Biochem Biophys Res Commun; 1994 Dec; 205(3):1702-6. PubMed ID: 7811254
[TBL] [Abstract][Full Text] [Related]
13. Pancreatic vasopressin V1b receptors: characterization in In-R1-G9 cells and localization in human pancreas.
Folny V; Raufaste D; Lukovic L; Pouzet B; Rochard P; Pascal M; Serradeil-Le Gal C
Am J Physiol Endocrinol Metab; 2003 Sep; 285(3):E566-76. PubMed ID: 12736162
[TBL] [Abstract][Full Text] [Related]
14. Leptin induces hypertrophy through activating the peroxisome proliferator-activated receptor α pathway in cultured neonatal rat cardiomyocytes.
Hou N; Luo MS; Liu SM; Zhang HN; Xiao Q; Sun P; Zhang GS; Luo JD; Chen MS
Clin Exp Pharmacol Physiol; 2010 Nov; 37(11):1087-95. PubMed ID: 20738325
[TBL] [Abstract][Full Text] [Related]
15. Mitogenic effect of arginine vasopressin on adult rat cardiac fibroblast: involvement of PKC-erk1/2 pathway.
Yan-ping H; Lian-you Z; Qiang-sun Z; Shao-wei L; Xiao-yan Z; Xiao-long L; Xiao-lin N; Xia L
J Cardiovasc Pharmacol; 2008 Jul; 52(1):72-81. PubMed ID: 18645411
[TBL] [Abstract][Full Text] [Related]
16. Lack of effect of a selective vasopressin V1A receptor antagonist SR 49,059, on potentiation by vasopressin of adrenoceptor-mediated pressor responses in the rat mesenteric arterial bed.
Heinemann A; Horina G; Stauber RE; Pertl C; Holzer P; Peskar BA
Br J Pharmacol; 1998 Nov; 125(6):1120-7. PubMed ID: 9863637
[TBL] [Abstract][Full Text] [Related]
17. Adenovirus-mediated overexpression of diacylglycerol kinase-zeta inhibits endothelin-1-induced cardiomyocyte hypertrophy.
Takahashi H; Takeishi Y; Seidler T; Arimoto T; Akiyama H; Hozumi Y; Koyama Y; Shishido T; Tsunoda Y; Niizeki T; Nozaki N; Abe J; Hasenfuss G; Goto K; Kubota I
Circulation; 2005 Mar; 111(12):1510-6. PubMed ID: 15781737
[TBL] [Abstract][Full Text] [Related]
18. OPC-41061, a highly potent human vasopressin V2-receptor antagonist: pharmacological profile and aquaretic effect by single and multiple oral dosing in rats.
Yamamura Y; Nakamura S; Itoh S; Hirano T; Onogawa T; Yamashita T; Yamada Y; Tsujimae K; Aoyama M; Kotosai K; Ogawa H; Yamashita H; Kondo K; Tominaga M; Tsujimoto G; Mori T
J Pharmacol Exp Ther; 1998 Dec; 287(3):860-7. PubMed ID: 9864265
[TBL] [Abstract][Full Text] [Related]
19. Cross talk between corticosteroids and alpha-adrenergic signalling augments cardiomyocyte hypertrophy: a possible role for SGK1.
Lister K; Autelitano DJ; Jenkins A; Hannan RD; Sheppard KE
Cardiovasc Res; 2006 Jun; 70(3):555-65. PubMed ID: 16533503
[TBL] [Abstract][Full Text] [Related]
20. Altered cardiovascular regulation in arginine vasopressin-overexpressing transgenic rat.
Tachikawa K; Yokoi H; Nagasaki H; Arima H; Murase T; Sugimura Y; Miura Y; Hirabayashi M; Oiso Y
Am J Physiol Endocrinol Metab; 2003 Dec; 285(6):E1161-6. PubMed ID: 12915399
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
